BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30487646)

  • 1. Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.
    Cantiello F; Russo GI; Kaufmann S; Cacciamani G; Crocerossa F; Ferro M; De Cobelli O; Artibani W; Cimino S; Morgia G; Damiano R; Nikolaou K; Kröger N; Stenzl A; Bedke J; Kruck S
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):206-220. PubMed ID: 30487646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
    Moldovan PC; Van den Broeck T; Sylvester R; Marconi L; Bellmunt J; van den Bergh RCN; Bolla M; Briers E; Cumberbatch MG; Fossati N; Gross T; Henry AM; Joniau S; van der Kwast TH; Matveev VB; van der Poel HG; De Santis M; Schoots IG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TB; Rouvière O
    Eur Urol; 2017 Aug; 72(2):250-266. PubMed ID: 28336078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latest Evidence on the Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Insignificant Prostate Cancer: A Systematic Review.
    Cantiello F; Manno S; Russo GI; Cimino S; Privitera S; Morgia G; Cicione A; Damiano R
    Anticancer Agents Med Chem; 2018; 18(7):925-930. PubMed ID: 29303080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: a systematic review and meta-analysis.
    Zhen L; Liu X; Yegang C; Yongjiao Y; Yawei X; Jiaqi K; Xianhao W; Yuxuan S; Rui H; Wei Z; Ningjing O
    BMC Cancer; 2019 Dec; 19(1):1244. PubMed ID: 31870327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance.
    Hsiang W; Ghabili K; Syed JS; Holder J; Nguyen KA; Suarez-Sarmiento A; Huber S; Leapman MS; Sprenkle PC
    Eur Urol Focus; 2021 Jan; 7(1):47-54. PubMed ID: 31147263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging in prostate cancer detection and management: a systematic review.
    Monni F; Fontanella P; Grasso A; Wiklund P; Ou YC; Randazzo M; Rocco B; Montanari E; Bianchi G
    Minerva Urol Nefrol; 2017 Dec; 69(6):567-578. PubMed ID: 28488844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Indeterminate Lesions on Magnetic Resonance Imaging-Biopsy Versus Surveillance: A Literature Review.
    Gómez Rivas J; Giganti F; Álvarez-Maestro M; Freire MJ; Kasivisvanathan V; Martinez-Piñeiro L; Emberton M
    Eur Urol Focus; 2019 Sep; 5(5):799-806. PubMed ID: 29525382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance.
    Glass AS; Dall'Era MA
    BJU Int; 2019 Nov; 124(5):730-737. PubMed ID: 30740876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
    Chu CE; Lonergan PE; Washington SL; Cowan JE; Shinohara K; Westphalen AC; Carroll PR; Cooperberg MR
    Eur Urol; 2020 Oct; 78(4):515-517. PubMed ID: 32631744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of multiparametric magnetic resonance imaging in the selection and follow-up of patients undergoing active surveillance for prostate cancer. An European Section of Uro-Technology (ESUT) review.
    Gómez Rivas J; Carrion DM; Chandrasekar T; Álvarez-Maestro M; Enikeev D; Martínez-Piñeiro L; Barret E
    Actas Urol Esp (Engl Ed); 2021 Apr; 45(3):188-197. PubMed ID: 33189417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biparametric vs multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatment-naïve patients: a diagnostic test accuracy systematic review and meta-analysis.
    Alabousi M; Salameh JP; Gusenbauer K; Samoilov L; Jafri A; Yu H; Alabousi A
    BJU Int; 2019 Aug; 124(2):209-220. PubMed ID: 30929292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
    Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
    BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
    Porpiglia F; Cantiello F; De Luca S; Manfredi M; Veltri A; Russo F; Sottile A; Damiano R
    BJU Int; 2016 Oct; 118(4):527-34. PubMed ID: 26350955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
    Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging?
    Jansen BHE; Nieuwenhuijzen JA; Oprea-Lager DE; Yska MJ; Lont AP; van Moorselaar RJA; Vis AN
    Urol Oncol; 2019 Mar; 37(3):181.e1-181.e6. PubMed ID: 30558983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What to expect from a non-suspicious prostate MRI? A review.
    Fiard G; Norris JM; Nguyen TA; Stavrinides V; Olivier J; Emberton M; Moore CM
    Prog Urol; 2020 Dec; 30(16):986-999. PubMed ID: 33008718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.
    Macleod LC; Yabes JG; Fam MM; Bandari J; Yu M; Maganty A; Furlan A; Filson CP; Davies BJ; Jacobs BL
    Eur Urol Focus; 2020 Mar; 6(2):242-248. PubMed ID: 31031042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.
    Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS
    Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.